Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care
To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen. A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in...
Gespeichert in:
| Veröffentlicht in: | Anticancer research 2018-02, Vol.38 (2), p.1033-1040 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1040 |
|---|---|
| container_issue | 2 |
| container_start_page | 1033 |
| container_title | Anticancer research |
| container_volume | 38 |
| creator | Hata, Masaharu Koike, Izumi Miyagi, Etsuko Asai-Sato, Mikiko Kaizu, Hisashi Mukai, Yuki Takano, Shoko Ito, Eiko Sugiura, Madoka Inoue, Tomio |
| description | To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen.
A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy.
In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p |
| doi_str_mv | 10.21873/anticanres.12319 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1993013469</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1993013469</sourcerecordid><originalsourceid>FETCH-LOGICAL-c324t-600459c317139cecb7627c45efaef537647e467a29cfa1dd10f5b65ea76c1f693</originalsourceid><addsrcrecordid>eNpdUctqHDEQFCEhXjv5gFyMIJdcxlGPRtLKN2eJH-DgsNjnQatpxTIz0lrSOvgf_NFW1psYAg0N1VXV3RQhn4AdtTBX_KsJxVsTEuYjaDnoN2QGSkOjBGdvyYy1gjWKMbFH9nO-Y0xKPefvyV6rueoUVzPytDSDN8XHQK9vMZn1I3Ux0Z8VwlAy_e3LLf0WA9IfWEyu5TN1KU70pmDyFV9geqhHjHRhgsV0TC-qbBlHpCYM9Gpd_FSHr2uW-MtPGHZrxvEP_FBtTMIP5J0zY8aPu35Abk6_Xy_Om8urs4vFyWVjeduVRjLWCW05KODaol0p2SrbCXQGneBKdgo7qUyrrTMwDMCcWEmBRkkLTmp-QL68-K5TvN9gLv3ks8VxNAHjJvegNWfAuy3183_Uu7hJoV7Xt8AVgGBzXlnwwrIp5pzQ9etU306PPbB-G1X_GlW_japqDnfOm9WEwz_F32z4M70Jks0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2137115083</pqid></control><display><type>article</type><title>Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Hata, Masaharu ; Koike, Izumi ; Miyagi, Etsuko ; Asai-Sato, Mikiko ; Kaizu, Hisashi ; Mukai, Yuki ; Takano, Shoko ; Ito, Eiko ; Sugiura, Madoka ; Inoue, Tomio</creator><creatorcontrib>Hata, Masaharu ; Koike, Izumi ; Miyagi, Etsuko ; Asai-Sato, Mikiko ; Kaizu, Hisashi ; Mukai, Yuki ; Takano, Shoko ; Ito, Eiko ; Sugiura, Madoka ; Inoue, Tomio</creatorcontrib><description>To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen.
A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy.
In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p<0.001) were significant prognostic factors for survival.
Radiation therapy is effective for relief of pelvic symptoms in patients with bone metastasis from uterine cervical cancer. For patients who are expected to survive for more than 1 year, almost curative-dose irradiation to primary tumors is recommended.</description><identifier>ISSN: 0250-7005</identifier><identifier>EISSN: 1791-7530</identifier><identifier>DOI: 10.21873/anticanres.12319</identifier><identifier>PMID: 29374737</identifier><language>eng</language><publisher>Greece: International Institute of Anticancer Research</publisher><subject>Bleeding ; Bone cancer ; Cancer ; Cancer therapies ; Cervical cancer ; Cervix ; Chemotherapy ; Identification methods ; Irradiation ; Medical prognosis ; Metastases ; Metastasis ; Pain ; Palliation ; Patients ; Pelvis ; Radiation ; Radiation dosage ; Radiation therapy ; Survival ; Tumors ; Uterine cancer ; Uterus</subject><ispartof>Anticancer research, 2018-02, Vol.38 (2), p.1033-1040</ispartof><rights>Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.</rights><rights>Copyright International Institute of Anticancer Research Feb 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29374737$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hata, Masaharu</creatorcontrib><creatorcontrib>Koike, Izumi</creatorcontrib><creatorcontrib>Miyagi, Etsuko</creatorcontrib><creatorcontrib>Asai-Sato, Mikiko</creatorcontrib><creatorcontrib>Kaizu, Hisashi</creatorcontrib><creatorcontrib>Mukai, Yuki</creatorcontrib><creatorcontrib>Takano, Shoko</creatorcontrib><creatorcontrib>Ito, Eiko</creatorcontrib><creatorcontrib>Sugiura, Madoka</creatorcontrib><creatorcontrib>Inoue, Tomio</creatorcontrib><title>Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen.
A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy.
In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p<0.001) were significant prognostic factors for survival.
Radiation therapy is effective for relief of pelvic symptoms in patients with bone metastasis from uterine cervical cancer. For patients who are expected to survive for more than 1 year, almost curative-dose irradiation to primary tumors is recommended.</description><subject>Bleeding</subject><subject>Bone cancer</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cervical cancer</subject><subject>Cervix</subject><subject>Chemotherapy</subject><subject>Identification methods</subject><subject>Irradiation</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Pain</subject><subject>Palliation</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Radiation</subject><subject>Radiation dosage</subject><subject>Radiation therapy</subject><subject>Survival</subject><subject>Tumors</subject><subject>Uterine cancer</subject><subject>Uterus</subject><issn>0250-7005</issn><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpdUctqHDEQFCEhXjv5gFyMIJdcxlGPRtLKN2eJH-DgsNjnQatpxTIz0lrSOvgf_NFW1psYAg0N1VXV3RQhn4AdtTBX_KsJxVsTEuYjaDnoN2QGSkOjBGdvyYy1gjWKMbFH9nO-Y0xKPefvyV6rueoUVzPytDSDN8XHQK9vMZn1I3Ux0Z8VwlAy_e3LLf0WA9IfWEyu5TN1KU70pmDyFV9geqhHjHRhgsV0TC-qbBlHpCYM9Gpd_FSHr2uW-MtPGHZrxvEP_FBtTMIP5J0zY8aPu35Abk6_Xy_Om8urs4vFyWVjeduVRjLWCW05KODaol0p2SrbCXQGneBKdgo7qUyrrTMwDMCcWEmBRkkLTmp-QL68-K5TvN9gLv3ks8VxNAHjJvegNWfAuy3183_Uu7hJoV7Xt8AVgGBzXlnwwrIp5pzQ9etU306PPbB-G1X_GlW_japqDnfOm9WEwz_F32z4M70Jks0</recordid><startdate>20180201</startdate><enddate>20180201</enddate><creator>Hata, Masaharu</creator><creator>Koike, Izumi</creator><creator>Miyagi, Etsuko</creator><creator>Asai-Sato, Mikiko</creator><creator>Kaizu, Hisashi</creator><creator>Mukai, Yuki</creator><creator>Takano, Shoko</creator><creator>Ito, Eiko</creator><creator>Sugiura, Madoka</creator><creator>Inoue, Tomio</creator><general>International Institute of Anticancer Research</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7T5</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20180201</creationdate><title>Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care</title><author>Hata, Masaharu ; Koike, Izumi ; Miyagi, Etsuko ; Asai-Sato, Mikiko ; Kaizu, Hisashi ; Mukai, Yuki ; Takano, Shoko ; Ito, Eiko ; Sugiura, Madoka ; Inoue, Tomio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c324t-600459c317139cecb7627c45efaef537647e467a29cfa1dd10f5b65ea76c1f693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Bleeding</topic><topic>Bone cancer</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cervical cancer</topic><topic>Cervix</topic><topic>Chemotherapy</topic><topic>Identification methods</topic><topic>Irradiation</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Pain</topic><topic>Palliation</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Radiation</topic><topic>Radiation dosage</topic><topic>Radiation therapy</topic><topic>Survival</topic><topic>Tumors</topic><topic>Uterine cancer</topic><topic>Uterus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hata, Masaharu</creatorcontrib><creatorcontrib>Koike, Izumi</creatorcontrib><creatorcontrib>Miyagi, Etsuko</creatorcontrib><creatorcontrib>Asai-Sato, Mikiko</creatorcontrib><creatorcontrib>Kaizu, Hisashi</creatorcontrib><creatorcontrib>Mukai, Yuki</creatorcontrib><creatorcontrib>Takano, Shoko</creatorcontrib><creatorcontrib>Ito, Eiko</creatorcontrib><creatorcontrib>Sugiura, Madoka</creatorcontrib><creatorcontrib>Inoue, Tomio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hata, Masaharu</au><au>Koike, Izumi</au><au>Miyagi, Etsuko</au><au>Asai-Sato, Mikiko</au><au>Kaizu, Hisashi</au><au>Mukai, Yuki</au><au>Takano, Shoko</au><au>Ito, Eiko</au><au>Sugiura, Madoka</au><au>Inoue, Tomio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2018-02-01</date><risdate>2018</risdate><volume>38</volume><issue>2</issue><spage>1033</spage><epage>1040</epage><pages>1033-1040</pages><issn>0250-7005</issn><eissn>1791-7530</eissn><abstract>To determine the role of radiation therapy for patients with bone metastasis from uterine cervical cancer and identify an optimal radiation regimen.
A total of 20 patients with bone metastases from uterine cervical cancer received radiation therapy to the pelvis. The median total dose of 60.2 Gy in the 2 Gy per fraction-equivalent dose (EQD2) was delivered to cervical tumors of all patients. Thirteen patients underwent chemotherapy during and/or following radiation therapy.
In 18 of 20 patients, the primary tumors disappeared or were markedly reduced after radiation therapy. In all but one of 17 patients with pelvic pain and bleeding, these symptoms disappeared or were remarkably relieved. However, three patients had primary tumor progression at 7, 9, and 15 months after irradiation with total doses of 56.8, 58.4, and 68.3 Gy in EQD2, respectively. Two of these patients had relapses of bleeding and pain. The primary progression-free rate considering all patients was 69% at 1 year and 34% at 2 years. The corresponding overall survival rates were 34% at 1 year, and 8% at 2 years, with an estimated median survival time of 7 months. The number of metastatic bone sites (p=0.027) and administration of chemotherapy (p<0.001) were significant prognostic factors for survival.
Radiation therapy is effective for relief of pelvic symptoms in patients with bone metastasis from uterine cervical cancer. For patients who are expected to survive for more than 1 year, almost curative-dose irradiation to primary tumors is recommended.</abstract><cop>Greece</cop><pub>International Institute of Anticancer Research</pub><pmid>29374737</pmid><doi>10.21873/anticanres.12319</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0250-7005 |
| ispartof | Anticancer research, 2018-02, Vol.38 (2), p.1033-1040 |
| issn | 0250-7005 1791-7530 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1993013469 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Bleeding Bone cancer Cancer Cancer therapies Cervical cancer Cervix Chemotherapy Identification methods Irradiation Medical prognosis Metastases Metastasis Pain Palliation Patients Pelvis Radiation Radiation dosage Radiation therapy Survival Tumors Uterine cancer Uterus |
| title | Radiation Therapy for Patients with Bone Metastasis from Uterine Cervical Cancer: Its Role and Optimal Radiation Regimen for Palliative Care |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-02T23%3A58%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Radiation%20Therapy%20for%20Patients%20with%20Bone%20Metastasis%20from%20Uterine%20Cervical%20Cancer:%20Its%20Role%20and%20Optimal%20Radiation%20Regimen%20for%20Palliative%20Care&rft.jtitle=Anticancer%20research&rft.au=Hata,%20Masaharu&rft.date=2018-02-01&rft.volume=38&rft.issue=2&rft.spage=1033&rft.epage=1040&rft.pages=1033-1040&rft.issn=0250-7005&rft.eissn=1791-7530&rft_id=info:doi/10.21873/anticanres.12319&rft_dat=%3Cproquest_cross%3E1993013469%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2137115083&rft_id=info:pmid/29374737&rfr_iscdi=true |